After months of speculation, Huawei‘s next-generation blood pressure monitoring smartwatch, the Watch D2, appears to be nearing launch. A recent leak on Weibo by tipster @UncleKanshan revealed that a Huawei wearablee has secured a Chinese medical device license.
This license, a requirement for selling medical equipment in China, signifies that the Watch D2 has undergone regulatory scrutiny and met specific medical device standards.
While the license itself doesn’t reveal the official name of the wearable, the listing refers to it as a “Wrist Ambulatory Blood Pressure Recorder. ” Also there are three watch variants in the license with model numbers LCA-B10, LCA-B11, and LCA-B12. All these details suggest that its the successor to the original Watch D.
We do not have much detail about the design or functionalities of the Huawei Watch D2. However, the licensing information confirms the presence of a main unit, a wristband, and a wireless charging base.
Feature-wise, its expected that the watch will be able to measure blood pressure, both systolic and diastolic blood pressure, alongside heart rate, in a static state for users aged 18 and above.
While not confirmed, Huawei D2 could launch alongside the upcoming Huawei Mate 70 flagship. This would align with previous rumors that placed the Watch D2’s release sometime this year.
Those familiar with the original Watch D can likely draw comparisons. The first iteration sported a boxy design with a 1.64-inch AMOLED display, offered features like blood pressure reminders and ECG analysis, and boasted a 7-day battery life.
It will be interesting to see how the Watch D2 builds upon this foundation. Will it offer improved battery life, a sleeker design, or introduce entirely new health-tracking features?
Comments